NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments
Abstract
The paper discusses the possibilities of using the NMDA receptor antagonist memantine in patients with vascular cognitive impairments (CIs). The author gives the data available in the literature and the results of her investigations into the efficiency and safety of treatment in patients with vascular dementia and moderate vascular CIs. The paper presents the results of a Russian multicenter trial of the efficacy and safety of akatinol memantine in patients with CIs, which enrolled 240 patients (mean age 69.5±5.5 years) with moderate CIs or mild dementia (the total Mini-Mental State Examination (MMSE) scores were 22–28). A study group included 148 patients who took akatinol memantine during a follow-up; a comparison group consisted of 92 patients who did not. Therapeutic effectiveness was evaluated using the quantitative neuropsychological scales and from changes in the somatic and neurological status and in the magnitude of emotional disorders at the inclusion in the study (before treatment initiation) and at 1.5, 3, and 6 months of therapy. During akatinol memantine therapy, there were significant reductions in the degree of CIs (lower total MMSE scores; p<0.00000), abnormalities in programming, generalization, and control over performed actions (a change in the total frontal lobe dysfunction battery scores;p<0.00000), and memory disorders, a significant increase in speech fluency (p<0.00000) and attention level (p< 0.00000), and a decrease in the degree of visuospatial deficits (p<0.00000). The effect of the therapy showed itself at its 3 months and continued to rise later on. The performed trial has indicated that akatinol memantine is an effective symptomatic drug to treat both moderate CIs and mild dementia.
About the Author
I.S. Preobrazhenskaya
Clinic of Nervous System Diseases, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia; 11, Rossolimo St., Build. 1, Moscow 119992
Russian Federation
Russian Federation
References
1. Arvanov VL, Chou HC, Chen RC, Tsai MC. Pre- and post-synaptic actions of memantine at cholinergic central synapse of achatina fulica. Comp Biochem Physiol. 1994;(107):305–11.
2. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett. 1988;86(1):109–13. DOI: http://dx.doi.org/10.1016/0304-3940(88)90192-9.
3. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7–62.
4. Kornhuber J, Wiltfang J. The role glutamate in dementia. J Neural Transm Suppl. 1998;(53):277–87.
5. DOI: http://dx.doi.org/10.1007/978-3-7091-6467-9_24.
6. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect.1998;11(9):523–69. DOI:http://dx.doi.org/10.1358/dnp.1998.11.9.863689.
7. Chan SL, Lu C, Mattson MP. Modification of cysteine proteases and AMPA receptor subunits by the lipid peroxidation product 4-hydroxynonenal: Impact on neuronal apoptosis and necrosis. Neurobiol Aging.
8. ;21(1S):S17. DOI: http://dx.doi.org/10.1016/S0197-4580(00)82755-4.
9. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. AJNR Am J Neuroradiol. 2001;22(10):1813–24.
10. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev. 1999;30(3):289–304. DOI:http://dx.doi.org/10.1016/S0165-0173(99)00020-X.
11. Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry.1995;28(4):113–24. DOI: http://dx.doi.org/10.1055/s-2007-979603.
12. Андросова ЛВ, Селезнева НД. Акатинол мемантин при болезни Альцгеймера: клинико-иммунологические корреляции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2000;100(9):36–8. [Androsova LV, Selezneva ND. Akatinol memantin at Alzheimer's disease: kliniko-immunological correlations. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;100(9):36–8. (In Russ.)]
13. Дамулин ИВ. Новая нейропротективная и терапевтическая стратегия при деменциях: антагонист NMDA-рецепторов Акатинол Мемантин. Русский медицинский журнал. 2001;9(25):1178–82. [Damulin IV. New neuroprotective and therapeutic strategy at dementias: antagonist of NMDA receptors Akatinol Memantin. Russkii meditsinskii zhurnal. 2001;9(25):1178–82. (In Russ.)]
14. Erkinjuntti T, Hachinski VC. Rethinking vascular dementia. Cerebrovasc Dis. 1993;(3):3–23. DOI: http://dx.doi.org/10.1159/000108661.
15. Foy CJ, Passmore AP, Vahidassr MD, et al. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM.1999;92(1):39–45. DOI: http://dx.doi.org/10.1093/qjmed/92.1.39.
16. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–47. DOI: http://dx.doi.org/10.1136/jnnp.66.2.137.
17. Sahin K, Stoeffler A, Furtuna P, et al. Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging. 2000;(21):S27. DOI: http://dx.doi.org/10.1016/S0197-4580(00)82798-0.
18. Danysz W, Parsons CG, Mobius H-J, et al. Neuroprotective and synptomatological action of memantine relevant for Alzheimer's disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2–3):85–97. DOI: http://dx.doi.org/10.1007/BF03033787.
19. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacol. 1999;38(6):735–67.
20. DOI: http://dx.doi.org/10.1016/S0028-3908(99)00019-2.
21. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–46. DOI: http://dx.doi.org/10.1002/(SICI)1099-1166(199902)14:2%3C135::AIDGPS906%
22. E3.0.CO;2-0.
23. Winblad B, Wimo A, Mobius HJ, et al. Severe dementia: a common condition entailing high costs at individual and societal levels. Int J Geriatr Psychiatry. 1999;14(11):911–4. DOI: http://dx.doi.org/10.1002/(SICI)1099-1166(199911)14:11%3C911::AIDGPS66%3E3.0.CO;2-I.
24. Reisberg B, Windscheif U, Ferris S, et al. Memantine in moderately severe to severe Alzheimer's disease: Results of placebo-controlled 6-month trial. Neurobiol Aging. 2000;(21):S275. DOI: http://dx.doi.org/10.1016/S0197-4580(00)83188-7.
25. Van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006;14(5):428–37. DOI: http://dx.doi.org/10.1097/01.JGP.0000203151.17311.38.
26. Orgogozo JM, Rigaud AS, Stö ffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–9. DOI: http://dx.doi.org/10.1161/01.STR.0000020094.08790.49.
27. Wilcock G, Mö bius HJ, Stö ffler A; MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297–305. DOI: http://dx.doi.org/10.1097/00004850-200211000-00005.
28. Яхно НН, Преображенская ИС, Захаров ВВ, Мхитарян ЭА. Эффективность акатинола мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;(2):52–8. [Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. Efficiency akatinol memantin at patients with nedementny cognitive frustration. Results of multicenter clinical supervision. Nevrologicheskii zhurnal. 2010;(2):52–8. (In Russ.)]
29. Захаров ВВ, Яхно НН. Синдром умеренных когнитивных нарушений в пожилом возрасте – диагностика и лечение. Русский медицинский журнал. 2004;12(10):573–6. [Zakharov VV, Yakhno NN. Syndrome of moderate cognitive violations at advanced age - diagnostics and treatment. Russkii meditsinskii zhurnal. 2004;12(10):573–6. (In Russ.)]
30. Парфенов ВА. Артериальная гипертония и инсульт. Неврологический журнал. 2001;6(6):4–7. [Parfenov VA. Arterial hypertension and stroke. Nevrologicheskii zhurnal. 2001;6(6):4–7. (In Russ.)]
31. Яхно НН, Парфенов ВА, Климов ЛВ. Когнитивные расстройства при ишемическом инсульте в каротидной системе. I Российский международный конгресс: цереброваскулярная патология и инсульт. Тезисы докладов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2003;9S:171. [Yakhno NN, Parfenov VA, Klimov LV. Cognitive frustration at an ischemic stroke in carotid system.
32. I Russian international congress: tserebrovaskulyarny pathology and stroke. Theses of reports. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2003;9S:171. (In Russ.)].
33. Парфенов ВА, Вахнина НВ. Артериальная гипертония и гипотензивная терапияпри ишемическом инсульте. Неврологический журнал. 2001;6(4):19–22. [Parfenov VA, Vakhnina NV. Arterial hypertension and hypotensive therapy at an ischemic stroke. Nevrologicheskii zhurnal. 2001;6(4):19–22. (In Russ.)]
34. Чердак МА, Парфенов ВА. Когнитивные расстройства у пациентов, перенесших ишемический инсульт: обзор. Неврологический журнал. 2011;16(6):37–44. [Cherdak MA, Parfenov VA. The cognitive impairments in patients after ischemic stroke. Nevrologicheskii zhurnal. 2011;16(6):37–44. (In Russ.)]
35. Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett. 1987;76(1):124–7. DOI:
36. http://dx.doi.org/10.1016/0304-3940(87)90204-7.
37. Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioral evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Zeitsch Gerontopsychol Psychiatry. 1993;(6):103–17.
38. Ruter E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D-Scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry.
39. ;33(3):103–8. DOI: http://dx.doi.org/10.1055/s-2000-341.
Review
For citations:
Preobrazhenskaya I. NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):69-74. (In Russ.) https://doi.org/10.14412/2074-2711-2014-2S-69-74
Views: 823
Email this article 